HK Stock Market Move | XUANZHUBIO-B(02575) Surges Over 40% in Afternoon Session, Signs Tripartite Commercial Agreement with Thailand's Innobic for Bilociclib Tablets

XUANZHUBIO-B(02575) surged over 40% in the afternoon session, rising 34.69% as of press time to HK$10.95, with a turnover of HK$92.8993 million. On the news front, XUANZHUBIO-B announced that the group has signed a tripartite commercial agreement (the "Agreement") with Thai pharmaceutical company Innobic (Asia) Co., Ltd ("Innobic (Asia)") and ZaoAn International Trading Co., Ltd ("ZaoAn International") regarding the group's Bilociclib Tablets (the "Target Product"). The agreement term expires on June 30, 2036. Pursuant to the Agreement, the group has jointly granted Innobic (Asia) and ZaoAn International exclusive commercialization rights for the Target Product in the Thailand region (the "Target Territory"). Such commercialization rights include the right to import, promote, market, offer for sale, sell, and distribute the Target Product in the Target Territory. Innobic (Asia) will act as the distributor, responsible for drug registration, local market marketing, and commercialization operations of the Target Product in the Target Territory. Pursuant to the Agreement, the marketing authorization for the Target Product will be held in the name of Innobic (Asia). This strategic collaboration is located in Thailand, one of the core member countries of the Pharmaceutical Inspection Co-operation Scheme (PIC/S). By leveraging international partners to expand into overseas markets, the company will continue to expand the influence of its products in the promising Southeast Asian market, bringing economic benefits to the company and enhancing its brand value.